<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="aprt-def" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">gene</book-id>
    <book-title-group>
      <book-title>GeneReviews<sup>&#x000ae;</sup></book-title>
    </book-title-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Adam</surname>
          <given-names>Margaret P</given-names>
        </name>
        <role>Editor-in-Chief</role>
      </contrib>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ardinger</surname>
          <given-names>Holly H</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Pagon</surname>
          <given-names>Roberta A</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Wallace</surname>
          <given-names>Stephanie E</given-names>
        </name>
      </contrib>
      <role>Senior Editors</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Bean</surname>
          <given-names>Lora JH</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Mefford</surname>
          <given-names>Heather C</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Stephens</surname>
          <given-names>Karen</given-names>
        </name>
      </contrib>
      <role>Molecular Genetics</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Amemiya</surname>
          <given-names>Anne</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ledbetter</surname>
          <given-names>Nikki</given-names>
        </name>
      </contrib>
      <role>Genetic Counseling</role>
    </contrib-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>1993</year>
    </pub-date>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>2017</year>
    </pub-date>
    <issn>2372-0697</issn>
    <publisher>
      <publisher-name>University of Washington, Seattle</publisher-name>
      <publisher-loc>Seattle (WA)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 1993-2017, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.</copyright-statement>
      <copyright-year>2017</copyright-year>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK138602/">
        <license-p>GeneReviews&#x000ae; chapters are owned by the University of Washington. Permission is hereby granted to reproduce, distribute, and translate copies of content materials for noncommercial research purposes only, provided that (i) credit for source (<ext-link ext-link-type="uri" xlink:href="http://www.genereviews.org/">http://www.genereviews.org/</ext-link>) and copyright (&#x000a9; 1993-2017 University of Washington) are included with each copy; (ii) a link to the original material is provided whenever the material is published elsewhere on the Web; and (iii) reproducers, distributors, and/or translators comply with the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>. No further modifications are allowed. For clarity, excerpts of GeneReviews chapters for use in lab reports and clinic notes are a permitted use.</license-p>
        <license-p>For more information, see the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>.</license-p>
        <license-p>For questions regarding permissions or whether a specified use is allowed, contact: <email>admasst@uw.edu</email>.</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Genetics</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Medicine</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Diseases</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="ednotes">
      <p content-type="genetic_counseling">
<italic toggle="yes">Genetic counseling is the process of
providing individuals and families with information on the nature, inheritance,
and implications of genetic disorders to help them make informed medical and
personal decisions. The following section deals with genetic risk assessment and
the use of family history and genetic testing to clarify genetic status for
family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with
a genetics professional</italic>. &#x02014;ED.</p>
      <p content-type="resources">
<italic toggle="yes">GeneReviews staff has selected the following disease-specific and/or
umbrella support organizations and/or registries for the benefit of individuals
with this disorder and their families. GeneReviews is not responsible for the
information provided by other organizations. For information on selection
criteria, click <related-object source-id="gene" document-id="app4">here</related-object>.</italic></p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">aprt-def</book-part-id>
      <title-group>
        <title>Adenine Phosphoribosyltransferase Deficiency</title>
        <alt-title alt-title-type="alt-title">Synonyms: 2,8-Dihydroxyadeninuria; APRT Deficiency</alt-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Edvardsson</surname>
            <given-names>Vidar Orn</given-names>
          </name>
          <degrees>MD</degrees>
          <email>vidare@landspitali.is</email>
          <aff>Division of Pediatric Nephrology<break/>Children&#x000b4;s Medical Center<break/>Landsp&#x000ed;tali - The National University Hospital of Iceland<break/>Reykjavik, Iceland</aff>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Palsson</surname>
            <given-names>Runolfur</given-names>
          </name>
          <degrees>MD</degrees>
          <email>runolfur@landspitali.is</email>
          <aff>Division of Nephrology<break/>Landsp&#x000ed;tali - The National University Hospital of Iceland<break/>University of Iceland<break/>Reykjavik, Iceland</aff>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Sahota</surname>
            <given-names>Amrik</given-names>
          </name>
          <degrees>PhD</degrees>
          <email>sahota@biology.rutgers.edu</email>
          <aff>Department of Genetics <break/>Rutgers University<break/>Piscataway, New Jersey</aff>
        </contrib>
      </contrib-group>
      <pub-history>
        <date iso-8601-date="2012-08-30" date-type="created">
          <day>30</day>
          <month>8</month>
          <year>2012</year>
        </date>
        <date iso-8601-date="2015-06-18" date-type="updated">
          <day>18</day>
          <month>6</month>
          <year>2015</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="gene">GeneReviews<sup>&#x000ae;</sup></related-object>
      <related-object link-type="previous-part-link" source-id="gene" document-id="adams-oliver" document-type="chapter">Adams-Oliver Syndrome</related-object>
      <related-object link-type="next-part-link" source-id="gene" document-id="ada" document-type="chapter">Adenosine Deaminase Deficiency</related-object>
      <abstract id="aprt-def.Summary">
        <title>Summary</title>
        <sec>
          <title>Clinical characteristics</title>
          <p>Adenine phosphoribosyltransferase (APRT) deficiency is characterized by excessive production of 2,8-dihydroxyadenine (DHA), which is excreted in the urine, where it is poorly soluble and leads to kidney stone formation and chronic kidney disease (CKD). Kidney stones, the most common clinical manifestation of APRT deficiency, can occur at any age; in at least 50% of affected individuals symptoms do not occur until adulthood. In a significant number of individuals, intratubular and interstitial precipitation of DHA crystals can result in kidney failure (i.e., DHA crystal nephropathy).</p>
        </sec>
        <sec>
          <title>Diagnosis/testing</title>
          <p>The detection of the characteristic round, brown DHA crystals by urine microscopy is highly suggestive of the disorder. The diagnosis is confirmed by absence of APRT enzyme activity in red cell lysates or identification of biallelic pathogenic variants in <italic toggle="yes">APRT</italic>.</p>
        </sec>
        <sec>
          <title>Management</title>
          <p><italic toggle="yes">Treatment of manifestations:</italic> Treatment with the xanthine dehydrogenase (XDH) inhibitor allopurinol can prevent or dissolve kidney stones and improve kidney function, even in individuals with advanced CKD. The XDH inhibitor febuxostat is an alternative option for those allergic to or intolerant of allopurinol. A low purine diet and ample fluid intake are recommended. Surgical management of DHA nephrolithiasis is the same as for other types of kidney stones. End-stage renal disease is treated with dialysis and kidney transplantation.</p>
          <p><italic toggle="yes">Prevention of primary manifestations:</italic> Lifelong treatment with allopurinol (or febuxostat) prevents or attenuates DHA crystalluria, nephrolithiasis, crystal nephropathy, and the development of kidney failure. The prescribed allopurinol dose should not routinely be reduced in affected individuals who have impaired kidney function.</p>
          <p><italic toggle="yes">Surveillance:</italic> Routine follow-up to facilitate medication compliance; consideration of periodic renal ultrasound examination to evaluate for new kidney stones.</p>
          <p><italic toggle="yes">Agents/circumstances to avoid:</italic> Azathioprine should be avoided by individuals taking XDH inhibitors.</p>
          <p><italic toggle="yes">Evaluation of relatives at risk:</italic> It is recommended that sibs of an affected individual undergo APRT enzyme activity measurement or molecular genetic testing (if the pathogenic variants in a family have been identified) to allow early diagnosis and treatment and improve long-term outcome.</p>
          <p><italic toggle="yes">Pregnancy management:</italic> The safety of allopurinol in human pregnancy has not been systematically studied. Some post-transplantation immunosuppressive therapies can have adverse effects on the developing fetus. Ideally a thorough discussion of the risks and benefits of maternal medication use during pregnancy should take place with an appropriate health care provider prior to conception.</p>
        </sec>
        <sec>
          <title>Genetic counseling</title>
          <p>APRT deficiency is inherited in an autosomal recessive manner. At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being normal. Carrier testing for at-risk relatives and prenatal diagnosis for pregnancies at increased risk are possible if the pathogenic variants in the family have been identified.</p>
        </sec>
      </abstract>
    </book-part-meta>
    <body>
      <sec id="aprt-def.Diagnosis">
        <title>Diagnosis</title>
        <sec id="aprt-def.Suggestive_Findings">
          <title>Suggestive Findings</title>
          <p><bold>Adenine phosphoribosyltransferase (APRT)</bold> deficiency (also known as 2,8-dihydroxyadeninuria) <bold>should be suspected</bold> in individuals with the following clinical, radiographic, laboratory, and pathology findings [<xref ref-type="bibr" rid="aprt-def.REF.edvardsson.2001.473">Edvardsson et al 2001</xref>, <xref ref-type="bibr" rid="aprt-def.REF.boll_e.2010.679">Boll&#x000e9;e et al 2010</xref>, <xref ref-type="bibr" rid="aprt-def.REF.nasr.2010.1909">Nasr et al 2010</xref>, <xref ref-type="bibr" rid="aprt-def.REF.edvardsson.2013.1923">Edvardsson et al 2013</xref>]:</p>
          <p>
            <bold>Clinical manifestations</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>A history of reddish-brown diaper stain, a frequent manifestation of DHA crystalluria in infants.</p>
            </list-item>
            <list-item>
              <p>Renal colic</p>
            </list-item>
            <list-item>
              <p>Chronic kidney disease (CKD) of unknown cause</p>
            </list-item>
            <list-item>
              <p>Crystal nephropathy</p>
            </list-item>
            <list-item>
              <p>Unexplained acute kidney injury (particularly in individuals with a history of radiolucent kidney stones)</p>
            </list-item>
          </list>
          <p>
            <bold>Radiographic findings</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Radiolucent kidney stones (based on imaging techniques capable of detecting radiolucent stones, e.g., ultrasound or computed tomography [CT]; stones are not seen on a plain abdominal x-ray)</p>
            </list-item>
          </list>
          <p>
            <bold>Laboratory findings</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>
                <bold>Urinalysis</bold>
              </p>
              <list list-type="bullet">
                <list-item>
                  <p><bold>Urine microscopy</bold>. The pathognomonic round and brown DHA crystals can usually be detected by urine microscopy (<xref ref-type="fig" rid="aprt-def.F1">Figure 1A</xref>). Small and medium sized DHA crystals display a central Maltese cross pattern when viewed by polarized light microscopy (<xref ref-type="fig" rid="aprt-def.F1">Figure 1B</xref>).Note: (1) DHA crystals may be difficult to identify in individuals with advanced CKD, possibly due to reduced clearance of the crystals by the kidney [<xref ref-type="bibr" rid="aprt-def.REF.edvardsson.2001.473">Edvardsson et al 2001</xref>, <xref ref-type="bibr" rid="aprt-def.REF.boll_e.2010.679">Boll&#x000e9;e et al 2010</xref>]. (2) High urine pH in individuals with radiolucent stones provides an additional clue to the diagnosis of APRT deficiency because uric acid stones develop in acidic urine (see <xref ref-type="sec" rid="aprt-def.Differential_Diagnosis">Differential Diagnosis</xref>).</p>
                </list-item>
                <list-item>
                  <p><bold>Testing for DHA.</bold> DHA can be identified in urine samples by high-performance liquid chromatography (HPLC) with UV detection or HPLC coupled with mass spectrometry.</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p><bold>Kidney stone analysis.</bold> Analysis of DHA crystals and kidney stone material using infrared or ultraviolet spectrophotometry (at both acidic and alkaline pH) and/or x-ray crystallography easily differentiates DHA from uric acid and xanthine, which also form radiolucent stones. Although stones in persons with APRT deficiency are predominantly composed of DHA, they may contain trace amounts of uric acid.Note: Stone analysis with standard chemical and thermogravimetric methods does not distinguish DHA from other purines (e.g., uric acid) and is no longer recommended.</p>
            </list-item>
          </list>
          <p>
            <bold>Pathology</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p><bold>Renal histopathologic examination.</bold> Renal histopathologic findings in persons with APRT deficiency and CKD or acute allograft dysfunction are characterized by diffuse DHA crystal deposits and tubulointerstitial abnormalities, even in the absence of a history of kidney stones (see <xref ref-type="fig" rid="aprt-def.F2">Figure 2</xref>) [<xref ref-type="bibr" rid="aprt-def.REF.edvardsson.2001.473">Edvardsson et al 2001</xref>, <xref ref-type="bibr" rid="aprt-def.REF.zaidan.2014.2623">Zaidan et al 2014</xref>].Note: It is important not to confuse the histopathologic manifestations of crystal nephropathy caused by APRT deficiency with those of other crystal nephropathies, particularly those caused by oxalate and uric acid deposits [<xref ref-type="bibr" rid="aprt-def.REF.nasr.2010.1909">Nasr et al 2010</xref>].</p>
            </list-item>
          </list>
        </sec>
        <sec id="aprt-def.Establishing_the_Diagnosis">
          <title>Establishing the Diagnosis</title>
          <p><bold>The diagnosis of APRT deficiency is established</bold> in a proband with the above <xref ref-type="sec" rid="aprt-def.Suggestive_Findings">suggestive findings</xref> and absent APRT enzyme activity in red cell lysates or by the identification of biallelic <italic toggle="yes">APRT</italic> pathogenic variants. A diagnostic algorithm is presented in <xref ref-type="fig" rid="aprt-def.F3">Figure 3</xref> [<xref ref-type="bibr" rid="aprt-def.REF.edvardsson.2013.1923">Edvardsson et al 2013</xref>].</p>
          <p><bold>APRT enzyme activity.</bold> APRT activity measured in red cell lysates ranges from 16 to 32 nmol/hr per mg hemoglobin in healthy individuals.</p>
          <p>APRT enzyme activity measured in red cell lysates (or other cell extracts) is absent in almost all individuals with APRT deficiency; however, exceptions occur. For example, two enzyme isoforms resulting from the following <italic toggle="yes">APRT</italic> pathogenic variants have substantial activity in red cell lysates:</p>
          <list list-type="bullet">
            <list-item>
              <p><xref ref-type="table" rid="aprt-def.T.selected_aprt_allelic_variant">p.Val150Phe</xref> [<xref ref-type="bibr" rid="aprt-def.REF.deng.2001.260">Deng et al 2001</xref>] (present in some individuals of northern European heritage)</p>
            </list-item>
            <list-item>
              <p><xref ref-type="table" rid="aprt-def.T.selected_aprt_allelic_variant">p.Met136Thr</xref> [<xref ref-type="bibr" rid="aprt-def.REF.sahota.2001">Sahota et al 2001</xref>] (present in &#x0003e;70% of Japanese, who are homozygous for this pathogenic variant)</p>
            </list-item>
          </list>
          <p>Thus, in individuals with these pathogenic variants, in vivo assays (e.g., uptake of adenine by intact erythrocytes or leukocytes) are required to verify APRT deficiency.</p>
          <p>Note: (1) If enzyme activity is within normal limits or in the heterozygote range in an individual who has recently received a red cell transfusion, enzyme activity measurement should be repeated after three months. (2) Heterozygotes for an <italic toggle="yes">APRT</italic> pathogenic variant cannot be reliably identified by enzyme assay in cell extracts as the enzyme activity range in these individuals overlaps with that of controls.</p>
          <p><bold>Molecular testing approaches</bold> include single-gene testing.</p>
          <list list-type="order">
            <list-item>
              <label>1</label>
              <p>Sequence analysis of <italic toggle="yes">APRT</italic> should be performed first.</p>
            </list-item>
            <list-item>
              <label>2</label>
              <p>If only one or no pathogenic variant is identified on sequence analysis, gene-targeted deletion/duplication analysis can be performed.</p>
            </list-item>
          </list>
          <table-wrap id="aprt-def.T.molecular_genetic_testing_use" position="anchor" orientation="portrait">
            <label>Table 1. </label>
            <caption>
              <p>Molecular Genetic Testing Used in Adenine Phosphoribosyltransferase Deficiency</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_aprt-def.T.molecular_genetic_testing_use_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Gene&#x000a0;<sup>1</sup></th>
                  <th id="hd_h_aprt-def.T.molecular_genetic_testing_use_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Test Method</th>
                  <th id="hd_h_aprt-def.T.molecular_genetic_testing_use_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Proportion of Probands with a Pathogenic Variant<sup>2</sup> Detectable by This Method</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_aprt-def.T.molecular_genetic_testing_use_1_1_1_1" rowspan="2" valign="middle" align="left" scope="row" colspan="1">
                    <italic toggle="yes">APRT</italic>
                  </td>
                  <td headers="hd_h_aprt-def.T.molecular_genetic_testing_use_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Sequence analysis&#x000a0;<sup>3,&#x000a0;4</sup></td>
                  <td headers="hd_h_aprt-def.T.molecular_genetic_testing_use_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">&#x0003e;95%&#x000a0;<sup>5</sup></td>
                </tr>
                <tr>
                  <td headers="hd_h_aprt-def.T.molecular_genetic_testing_use_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Gene-targeted deletion/duplication analysis&#x000a0;<sup>6</sup></td>
                  <td headers="hd_h_aprt-def.T.molecular_genetic_testing_use_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">See footnote 7</td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn id="aprt-def.TF.1.1">
                <label>1. </label>
                <p>See <related-object source-id="gene" document-id="aprt-def" object-id="aprt-def.molgen.TA">Table A. Genes and Databases</related-object> for chromosome locus and protein.</p>
              </fn>
              <fn id="aprt-def.TF.1.2">
                <label>2. </label>
                <p>See <xref ref-type="sec" rid="aprt-def.Molecular_Genetics">Molecular Genetics</xref> for information on allelic variants detected in this gene.</p>
              </fn>
              <fn id="aprt-def.TF.1.3">
                <label>3. </label>
                <p>Sequence analysis detects variants that are benign, likely benign, of uncertain significance, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants; typically, exon or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click <related-object link-type="booklink" source-id="gene" document-id="app2" document-type="appendix">here</related-object>.</p>
              </fn>
              <fn id="aprt-def.TF.1.4">
                <label>4. </label>
                <p>More than 40 pathogenic variants have been identified in the coding region of <italic toggle="yes">APRT</italic> in over 300 affected individuals from more than 25 countries, including at least 200 individuals from Japan (see <xref ref-type="sec" rid="aprt-def.Molecular_Genetics">Molecular Genetics</xref>).</p>
              </fn>
              <fn id="aprt-def.TF.1.5">
                <label>5. </label>
                <p>Pathogenic variants in <italic toggle="yes">APRT</italic> have not been identified in at least five individuals with APRT deficiency and it remains to be determined whether these pathogenic variants occur outside of the <italic toggle="yes">APRT</italic> coding region or are due to epigenetic changes.</p>
              </fn>
              <fn id="aprt-def.TF.1.6">
                <label>6. </label>
                <p>Gene-targeted deletion/duplication analysis detects intragenic deletions or duplications. Methods that may be used can include: quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a gene-targeted microarray designed to detect single-exon deletions or duplications.</p>
              </fn>
              <fn id="aprt-def.TF.1.7">
                <label>7. </label>
                <p>Four described deletions include (see <xref ref-type="sec" rid="aprt-def.Molecular_Genetics">Molecular Genetics</xref>): a large homozygous contiguous gene deletion (~100 kb) [<xref ref-type="bibr" rid="aprt-def.REF.wang.1999.78">Wang et al 1999</xref>] a 254-kb deletion in two families (one from Austria and the other from Italy) [<xref ref-type="bibr" rid="aprt-def.REF.menardi.1997.251">Menardi et al 1997</xref>, <xref ref-type="bibr" rid="aprt-def.REF.di_pietro.2007.73">Di Pietro et al 2007</xref>], and an uncharacterized large deletion in two individuals from Japan [<xref ref-type="bibr" rid="aprt-def.REF.kamatani.1992.130">Kamatani et al 1992</xref>].</p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
          <p>Note that enzyme activity measurements in cell extracts alone may not be sufficient to determine the functional significance of novel variants. (See <xref ref-type="sec" rid="aprt-def.Establishing_the_Diagnosis">APRT enzyme activity</xref>.)</p>
        </sec>
      </sec>
      <sec id="aprt-def.Clinical_Characteristics">
        <title>Clinical Characteristics</title>
        <sec id="aprt-def.Clinical_Description">
          <title>Clinical Description</title>
          <p>Kidney stones are the most common clinical manifestation of APRT deficiency in both children and adults [<xref ref-type="bibr" rid="aprt-def.REF.edvardsson.2001.473">Edvardsson et al 2001</xref>, <xref ref-type="bibr" rid="aprt-def.REF.harambat.2012.571">Harambat et al 2012</xref>] and CKD is the second most common manifestation in adults [<xref ref-type="bibr" rid="aprt-def.REF.edvardsson.2001.473">Edvardsson et al 2001</xref>, <xref ref-type="bibr" rid="aprt-def.REF.harambat.2012.571">Harambat et al 2012</xref>]. Acute kidney injury due to bilateral DHA calculi and urinary tract obstruction is a well-recognized presentation in children [<xref ref-type="bibr" rid="aprt-def.REF.debray.1976.762">Debray et al 1976</xref>, <xref ref-type="bibr" rid="aprt-def.REF.greenwood.1982.346">Greenwood et al 1982</xref>, <xref ref-type="bibr" rid="aprt-def.REF.chiba.1988.141">Chiba et al 1988</xref>, <xref ref-type="bibr" rid="aprt-def.REF.edvardsson.2001.473">Edvardsson et al 2001</xref>].</p>
          <p>APRT deficiency may present at any age; there is no typical age of onset. In a recently reported French series [<xref ref-type="bibr" rid="aprt-def.REF.boll_e.2010.679">Boll&#x000e9;e et al 2010</xref>], only 37% of individuals with APRT deficiency were diagnosed before age 16 years. The median (range) age at diagnosis in 33 Icelandic individuals with data in the APRT Deficiency Registry of the Rare Kidney Stone Consortium was 27.3 (0.6-62.7) years. Sixteen (48%) of these 33 individuals first presented in childhood (&#x0003c;18 years) at a median age of 2.2 (0.2-16.5) years [unpublished observations].</p>
          <p>Many children, however, remain asymptomatic and in at least half of instances the diagnosis of APRT deficiency is not made until adulthood. Of note, abdominal ultrasound and CT examinations performed for other reasons may identify kidney stones in individuals with APRT deficiency who may be asymptomatic. In a significant number of asymptomatic individuals, APRT deficiency has been diagnosed by the detection of DHA crystals on routine urine microscopy or through the screening of sibs of affected individuals [<xref ref-type="bibr" rid="aprt-def.REF.edvardsson.2001.473">Edvardsson et al 2001</xref>, <xref ref-type="bibr" rid="aprt-def.REF.harambat.2012.571">Harambat et al 2012</xref>].</p>
          <p>The majority of symptomatic individuals with APRT deficiency experience recurrent DHA kidney stones, abdominal pain, and/ or lower urinary tract symptoms for years. They also frequently develop CKD secondary to DHA crystal nephropathy in which the crystals are typically located in tubular lumina, inside renal epithelial cells, and in the interstitium.</p>
          <p>Studies have shown that 15% of individuals had progressed to end-stage renal disease (ESRD) at the time of diagnosis of APRT deficiency [<xref ref-type="bibr" rid="aprt-def.REF.edvardsson.2001.473">Edvardsson et al 2001</xref>, <xref ref-type="bibr" rid="aprt-def.REF.boll_e.2010.679">Boll&#x000e9;e et al 2010</xref>, <xref ref-type="bibr" rid="aprt-def.REF.harambat.2012.571">Harambat et al 2012</xref>]. In some of these individuals the diagnosis was not made until after kidney transplantation [<xref ref-type="bibr" rid="aprt-def.REF.benedetto.2001.e37">Benedetto et al 2001</xref>, <xref ref-type="bibr" rid="aprt-def.REF.cassidy.2004.736">Cassidy et al 2004</xref>, <xref ref-type="bibr" rid="aprt-def.REF.zaidan.2014.2623">Zaidan et al 2014</xref>].</p>
          <p>APRT deficiency is not known to affect organs other than the kidney; however, the authors and other investigators have encountered occasional individuals with APRT deficiency complaining of eye discomfort [<xref ref-type="bibr" rid="aprt-def.REF.neetens.1986.93">Neetens et al 1986</xref>; Author, personal observation], which merits further study.</p>
        </sec>
        <sec id="aprt-def.GenotypePhenotype_Correlations">
          <title>Genotype-Phenotype Correlations</title>
          <p>No genotype-phenotype correlations have been established; clinical features are known to vary greatly between individuals with the same pathogenic variants [<xref ref-type="bibr" rid="aprt-def.REF.edvardsson.2001.473">Edvardsson et al 2001</xref>, <xref ref-type="bibr" rid="aprt-def.REF.boll_e.2010.679">Boll&#x000e9;e et al 2010</xref>].</p>
        </sec>
        <sec id="aprt-def.Nomenclature">
          <title>Nomenclature</title>
          <p>Originally, two types of APRT deficiency with identical clinical manifestations were described, based on the level of residual APRT activity in cell extracts (erythrocyte lysates) [<xref ref-type="bibr" rid="aprt-def.REF.sahota.2001">Sahota et al 2001</xref>]. However, this distinction is of historic interest only, as APRT enzyme activity in intact cells has been shown to be less than 1% in both types [<xref ref-type="bibr" rid="aprt-def.REF.kamatani.1985.164">Kamatani et al 1985</xref>] (See <xref ref-type="sec" rid="aprt-def.Establishing_the_Diagnosis">Establishing the Diagnosis</xref>, <bold>APRT enzyme activity</bold>).</p>
        </sec>
        <sec id="aprt-def.Prevalence">
          <title>Prevalence</title>
          <p>The estimated heterozygote frequency in different populations ranges from 0.4 to 1.2% [<xref ref-type="bibr" rid="aprt-def.REF.hidaka.1987.1409">Hidaka et al 1987</xref>, <xref ref-type="bibr" rid="aprt-def.REF.sahota.2001">Sahota et al 2001</xref>], suggesting that the prevalence of a homozygous state is at least 1:50,000 to 1:100,000.</p>
          <p>If this holds true, at least 70,000-80,000 individuals should be affected worldwide, of whom 40,000 would be expected to be in Asia, 9000 in Europe, and 8000 in the Americas, including at least 3000 affected individuals in the US alone. Most of these individuals are currently unrecognized (and thus, not benefitting from medical therapy).</p>
          <p>Evidence suggests that APRT deficiency may be a seriously underrecognized cause of kidney stones and crystal nephropathy, progressing over time to ESRD in a significant proportion of untreated individuals [<xref ref-type="bibr" rid="aprt-def.REF.zaidan.2014.2623">Zaidan et al 2014</xref>].</p>
        </sec>
      </sec>
      <sec id="aprt-def.Genetically_Related_Allelic_Dis">
        <title>Genetically Related (Allelic) Disorders</title>
        <p>No phenotypes other than those discussed in this <italic toggle="yes">GeneReview</italic> have been associated with mutation of <italic toggle="yes">APRT.</italic></p>
      </sec>
      <sec id="aprt-def.Differential_Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Differential diagnosis of APRT deficiency includes other known causes of radiolucent kidney stones such as uric acid nephrolithiasis (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/605990">605990</ext-link>) and xanthinuria (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/278300">278300</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/603592">603592</ext-link>).</p>
        <p>The diagnosis of APRT deficiency should be considered in all individuals with CKD or kidney failure, particularly in those with renal histopathologic features of crystal nephropathy, even in the absence of a history of nephrolithiasis.</p>
      </sec>
      <sec id="aprt-def.Management_1">
        <title>Management</title>
        <sec id="aprt-def.Evaluations_Following_Initial_D">
          <title>Evaluations Following Initial Diagnosis</title>
          <p>To establish the extent of disease and needs of an individual diagnosed with APRT deficiency, the following evaluations are recommended:</p>
          <list list-type="bullet">
            <list-item>
              <p>Assessment of kidney involvement:</p>
              <list list-type="bullet">
                <list-item>
                  <p>Measure serum creatinine concentration.</p>
                </list-item>
                <list-item>
                  <p>Screen for albuminuria or proteinuria.</p>
                </list-item>
                <list-item>
                  <p>Assess kidney stone burden with ultrasound or CT examination.</p>
                </list-item>
                <list-item>
                  <p>Perform kidney biopsy in individuals with reduced renal function and/or proteinuria.</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p>Ophthalmology consultation if eye symptoms are present</p>
            </list-item>
            <list-item>
              <p>Consideration of consultation with a medical geneticist and/or genetic counselor</p>
            </list-item>
          </list>
        </sec>
        <sec id="aprt-def.Treatment_of_Manifestations">
          <title>Treatment of Manifestations</title>
          <p><bold>Allopurinol.</bold> Treatment with the XDH inhibitor allopurinol is effective and generally well-tolerated in individuals with APRT deficiency. Allopurinol 5-10 mg/kg/day (maximum daily dose 800 mg), either once daily or in two divided doses, minimizes DHA crystalluria, stone formation, crystal deposition in the kidney, and the development of kidney failure [<xref ref-type="bibr" rid="aprt-def.REF.edvardsson.2001.473">Edvardsson et al 2001</xref>, <xref ref-type="bibr" rid="aprt-def.REF.boll_e.2010.679">Boll&#x000e9;e et al 2010</xref>]. Treatment with allopurinol can even dissolve DHA kidney stones and improve kidney function in individuals with advanced CKD [<xref ref-type="bibr" rid="aprt-def.REF.edvardsson.2001.473">Edvardsson et al 2001</xref>, <xref ref-type="bibr" rid="aprt-def.REF.boll_e.2010.679">Boll&#x000e9;e et al 2010</xref>]. Allopurinol treatment is monitored by clinical evaluation and urine microscopy; the absence of urinary DHA crystals is indicative of adequate therapy.</p>
          <p><bold>Febuxostat.</bold> The recently introduced XDH inhibitor febuxostat provides an alternative treatment option for affected individuals allergic to or intolerant of allopurinol [<xref ref-type="bibr" rid="aprt-def.REF.becker.2005.916">Becker et al 2005</xref>]. The complete disappearance of urinary DHA crystals was recently described in an indvidual with APRT deficiency treated with febuxostat in the daily dose of 80 mg [<xref ref-type="bibr" rid="aprt-def.REF.arnad_ttir.2014.316">Arnad&#x000f3;ttir 2014</xref>]. Furthermore, the authors of this review have noted a significant reduction or even disappearance of DHA crystalluria in several adult individuals with APRT deficiency treated with a daily febuxostat dose of 80 mg [unpublished observations].</p>
          <p><bold>Low purine diet</bold> and <bold>ample fluid intake</bold> provide adjunctive benefits to pharmacologic therapy.</p>
          <p><bold>Surgical management of DHA kidney stones</bold> is the same as for the management of other types of stones, including extracorporeal shock-wave lithotripsy.</p>
          <p>
            <bold>Treatment of ESRD</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p><bold>Dialysis.</bold> Of note, it is not known if individuals with APRT deficiency on dialysis benefit from allopurinol therapy. The allopurinol dose should not routinely be reduced in affected individuals who have impaired kidney function.</p>
            </list-item>
            <list-item>
              <p><bold>Kidney transplantation.</bold> All individuals with APRT deficiency undergoing kidney transplantation require treatment with allopurinol (or febuxostat) for at least six weeks prior to transplant surgery, whenever possible. Affected individuals who have undergone kidney transplantation require lifelong therapy with allopurinol (or febuxostat) to prevent recurrent DHA crystal nephropathy in the transplanted organ.</p>
            </list-item>
          </list>
        </sec>
        <sec id="aprt-def.Prevention_of_Primary_Manifesta">
          <title>Prevention of Primary Manifestations</title>
          <p>Adequate treatment of APRT deficiency with allopurinol (or febuxostat in those who are allergic to or intolerant of allopurinol) prevents kidney stone formation and the development of CKD in most, if not all, individuals with the disorder [<xref ref-type="bibr" rid="aprt-def.REF.edvardsson.2001.473">Edvardsson et al 2001</xref>, <xref ref-type="bibr" rid="aprt-def.REF.boll_e.2010.679">Boll&#x000e9;e et al 2010</xref>, <xref ref-type="bibr" rid="aprt-def.REF.harambat.2012.571">Harambat et al 2012</xref>]. Therefore, all affected individuals should receive lifelong treatment with allopurinol (or febuxostat).</p>
        </sec>
        <sec id="aprt-def.Surveillance">
          <title>Surveillance</title>
          <p>No surveillance guidelines have been developed. However, all individuals with APRT deficiency should see their physician every six to 12 months to:</p>
          <list list-type="bullet">
            <list-item>
              <p>Monitor kidney function;</p>
            </list-item>
            <list-item>
              <p>Assess the urinary excretion of DHA crystals (disappearance of the crystals is considered an adequate treatment response);</p>
            </list-item>
            <list-item>
              <p>Facilitate medication compliance.</p>
            </list-item>
          </list>
          <p>Periodic renal ultrasound examinations may be considered to evaluate for new kidney stones.</p>
        </sec>
        <sec id="aprt-def.AgentsCircumstances_to_Avoid">
          <title>Agents/Circumstances to Avoid</title>
          <p>Azathioprine should be avoided by individuals taking XDH inhibitors.</p>
        </sec>
        <sec id="aprt-def.Evaluation_of_Relatives_at_Risk">
          <title>Evaluation of Relatives at Risk</title>
          <p>Once the pathogenic variants in a family have been identified, it is recommended that sibs of an affected individual undergo molecular genetic testing or APRT enzyme activity measurements to allow early diagnosis and treatment in order to improve long-term outcome. Further investigations, including assessment of renal function and urinalysis, are warranted in individuals with biallelic pathogenic variants.</p>
          <p>Note: Approximately 15% of individuals with APRT deficiency may be asymptomatic [<xref ref-type="bibr" rid="aprt-def.REF.edvardsson.2001.473">Edvardsson et al 2001</xref>, <xref ref-type="bibr" rid="aprt-def.REF.boll_e.2010.679">Boll&#x000e9;e et al 2010</xref>]; they are usually identified during family screening.</p>
          <p>See <xref ref-type="sec" rid="aprt-def.Related_Genetic_Counseling_Issu">Genetic Counseling</xref> for issues related to testing of at-risk relatives for genetic counseling purposes.</p>
        </sec>
        <sec id="aprt-def.Pregnancy_Management">
          <title>Pregnancy Management</title>
          <p>The safety of allopurinol in human pregnancy has not been systematically studied.</p>
          <p>Animal studies using high doses of allopurinol have revealed evidence of adverse fetal effects in mice but not in rats or rabbits; it is not clear if these effects are a result of direct fetal toxicity or maternal toxicity. Thus, allopurinol should only be prescribed during pregnancy when the benefit of treatment is believed to outweigh the risk. Treatment with allopurinol during pregnancy should be considered in women with APRT deficiency who have CKD with reduced glomerular filtration rate (GFR) or who have undergone kidney transplantation.</p>
          <p>Some post-transplantation immunosuppressive therapies can also have adverse effects on the developing fetus.</p>
          <p>A thorough discussion of the risks and benefits of maternal medication use during pregnancy should ideally take place with an appropriate health care provider prior to conception.</p>
        </sec>
        <sec id="aprt-def.Therapies_Under_Investigation">
          <title>Therapies Under Investigation</title>
          <p>Search <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://clinicaltrials.gov/">Clinical Trials.gov</ext-link> for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.</p>
        </sec>
      </sec>
      <sec id="aprt-def.Genetic_Counseling">
        <title>Genetic Counseling</title>
        <sec id="aprt-def.Mode_of_Inheritance">
          <title>Mode of Inheritance</title>
          <p>APRT deficiency is inherited in an autosomal recessive manner.</p>
        </sec>
        <sec id="aprt-def.Risk_to_Family_Members">
          <title>Risk to Family Members</title>
          <p>
            <bold>Parents of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The parents of an affected individual are obligate heterozygotes (i.e., carriers of one <italic toggle="yes">APRT</italic> pathogenic variant).</p>
            </list-item>
            <list-item>
              <p>Heterozygotes (carriers) are asymptomatic, urine microscopy does not reveal DHA crystals, and they are not at risk of developing the disorder.</p>
            </list-item>
          </list>
          <p>
            <bold>Sibs of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>At conception, each sib of an affected individual has a 25% chance of inheriting two <italic toggle="yes">APRT</italic> pathogenic variants, a 50% chance of inheriting one pathogenic variant and being an asymptomatic carrier, and a 25% chance of inheriting two benign alleles.</p>
            </list-item>
            <list-item>
              <p>Approximately 15%-20% of individuals who have inherited two <italic toggle="yes">APRT</italic> pathogenic variants may be asymptomatic despite their abnormal urinary DHA excretion [<xref ref-type="bibr" rid="aprt-def.REF.edvardsson.2001.473">Edvardsson et al 2001</xref>, <xref ref-type="bibr" rid="aprt-def.REF.boll_e.2010.679">Boll&#x000e9;e et al 2010</xref>]. Such individuals are usually identified during family screening.</p>
            </list-item>
            <list-item>
              <p>Once an at-risk sib is known to be unaffected, the risk of his/her being a carrier of an <italic toggle="yes">APRT</italic> pathogenic variant is 2/3.</p>
            </list-item>
            <list-item>
              <p>Heterozygotes (carriers) are asymptomatic, urine microscopy does not reveal DHA crystals, and they are not at risk of developing the disorder.</p>
            </list-item>
          </list>
          <p><bold>Offspring of a proband.</bold> The offspring of an individual with APRT deficiency are obligate heterozygotes (carriers) for a pathogenic variant in <italic toggle="yes">APRT</italic>.</p>
          <p><bold>Other family members.</bold> Each sib of the proband&#x02019;s parents is at a 50% risk of being a carrier of an <italic toggle="yes">APRT</italic> pathogenic variant.</p>
        </sec>
        <sec id="aprt-def.Carrier_Detection">
          <title>Carrier Detection</title>
          <p>Carrier testing for at-risk family members is possible if the pathogenic variants in the family have been identified.</p>
        </sec>
        <sec id="aprt-def.Related_Genetic_Counseling_Issu">
          <title>Related Genetic Counseling Issues</title>
          <p>See Management, <xref ref-type="sec" rid="aprt-def.Evaluation_of_Relatives_at_Risk">Evaluation of Relatives at Risk</xref> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p>
          <p><bold>Testing of at-risk asymptomatic sibs</bold> of individuals with APRT deficiency is possible after molecular genetic testing has identified the specific pathogenic variants in the family. Because an effective treatment is available, this testing is appropriate to consider for at-risk sibs regardless of age. However, such testing should be performed in the context of formal genetic counseling, and is not useful in predicting age of onset, severity, type of symptoms, or rate of progression in asymptomatic individuals.</p>
          <p>
            <bold>Family planning</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The optimal time for determination of genetic risk, clarification of carrier status, and discussion of the availability of prenatal testing is before pregnancy.</p>
            </list-item>
            <list-item>
              <p>It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to young adults who are affected, are carriers, or are at risk of being carriers.</p>
            </list-item>
          </list>
          <p><bold>DNA banking</bold> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of affected individuals.</p>
        </sec>
        <sec id="aprt-def.Prenatal_Testing">
          <title>Prenatal Testing</title>
          <p>If the <italic toggle="yes">APRT</italic> pathogenic variants have been identified in an affected family member, prenatal testing for pregnancies at increased risk may be available from a clinical laboratory that offers either testing of this gene or custom prenatal testing.</p>
          <p>Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing, particularly if the testing is being considered for the purpose of pregnancy termination rather than early diagnosis. Although decisions about prenatal testing are the choice of the parents, discussion of these issues is appropriate.</p>
          <p><bold>Preimplantation genetic diagnosis (PGD)</bold> may be an option for some families in which the <italic toggle="yes">APRT</italic> pathogenic variants have been identified.</p>
        </sec>
      </sec>
      <sec id="aprt-def.Resources">
        <title>Resources</title>
      </sec>
      <sec id="aprt-def.Molecular_Genetics">
        <title>Molecular Genetics</title>
        <p><bold>Gene structure.</bold>
<italic toggle="yes">APRT</italic> spans 2.8 kb of genomic DNA. The gene contains 5 exons and has a coding region of 540 bp. For a detailed summary of gene and protein information, see <related-object source-id="gene" document-id="aprt-def" object-id="aprt-def.molgen.TA">Table A</related-object>, <bold>Gene</bold>.</p>
        <p><bold>Benign allelic variants.</bold> Fourteen benign allelic variants have been identified in the sequences flanking <italic toggle="yes">APRT</italic> [<xref ref-type="bibr" rid="aprt-def.REF.sahota.2001">Sahota et al 2001</xref>]. Six of these normal variants were located in a 1.2-kb fragment upstream of the initiation codon and eight were located in a 1.8-kb fragment downstream of the termination codon. The majority were identified in both white and Japanese individuals. In addition, four normal variants in introns have been reported in individuals from Japan.</p>
        <p>All affected individuals of Japanese ancestry with the c.329G&#x0003e;A (p.Trp98Ter) pathogenic variant examined to date have a silent base substitution at codon 99 (GCC to GCT, Ala).</p>
        <p><bold>Pathogenic allelic variants.</bold> APRT deficiency is caused by homozygous or compound heterozygous mutations within <italic toggle="yes">APRT</italic>. A subset of the pathogenic allelic variants are listed in <xref ref-type="table" rid="aprt-def.T.selected_aprt_allelic_variant">Table 2</xref>. More than 40 pathogenic variants have been identified in the coding region of <italic toggle="yes">APRT</italic> in over 300 affected individuals from more than 25 countries, including at least 200 individuals from Japan. Approximately 10% of mutant alleles in affected white individuals and 5% in affected Japanese individuals remain to be identified [<xref ref-type="bibr" rid="aprt-def.REF.sahota.2001">Sahota et al 2001</xref>, <xref ref-type="bibr" rid="aprt-def.REF.boll_e.2010.679">Boll&#x000e9;e et al 2010</xref>]. Pathogenic variants include missense, frameshift, and nonsense variants and small deletions/insertions ranging in size from one to eight base pairs.</p>
        <p>The most common pathogenic variants in affected white individuals are:</p>
        <list list-type="bullet">
          <list-item>
            <p>c.400+2dupT, leading to deletion of exon 4 due to aberrant splicing. This pathogenic variant has been found in individuals from many European countries as well as in an affected individual from the US.</p>
          </list-item>
          <list-item>
            <p>c.194A&#x0003e;T, in exon 3, described in affected individuals from Iceland, Britain, and Spain.</p>
          </list-item>
        </list>
        <p>The three most common pathogenic variants in affected Japanese individuals, in order of decreasing frequency, are:</p>
        <list list-type="bullet">
          <list-item>
            <p>c.407T&#x0003e;C, in exon 5</p>
          </list-item>
          <list-item>
            <p>c.294G&#x0003e;A, in exon 3</p>
          </list-item>
          <list-item>
            <p>c.258_261dupCCGA, in exon 3</p>
          </list-item>
        </list>
        <p>
          <bold>Large deletions and contiguous gene rearrangements</bold>
        </p>
        <list list-type="bullet">
          <list-item>
            <p>A contiguous gene deletion of <italic toggle="yes">APRT</italic> and <italic toggle="yes">GALNS</italic> can result in APRT deficiency and Morquio syndrome. One affected individual from the Czech Republic who was homozygous for a contiguous gene deletion involving <italic toggle="yes">APRT</italic> and <italic toggle="yes">GALNS</italic> has been reported [<xref ref-type="bibr" rid="aprt-def.REF.wang.1999.78">Wang et al 1999</xref>]. The size of the deletion was approximately 100 kb and it spanned the region distal to <italic toggle="yes">GALNS</italic> exon 2 and proximal to <italic toggle="yes">APRT</italic> exon 3.</p>
          </list-item>
          <list-item>
            <p>A Japanese individual with hemizygosity for <italic toggle="yes">APRT</italic> and <italic toggle="yes">GALNS</italic> has been reported [<xref ref-type="bibr" rid="aprt-def.REF.fukuda.1996.123">Fukuda et al 1996</xref>]. A single nucleotide variant in the other <italic toggle="yes">GALNS</italic> allele accounted for the loss of GALNS activity. A second mutant <italic toggle="yes">APRT</italic> allele was not identified and the individual was not reported to be symptomatic for APRT deficiency.</p>
          </list-item>
          <list-item>
            <p>A 254-kb deletion was reported in two families: one from Austria and the other from Italy [<xref ref-type="bibr" rid="aprt-def.REF.menardi.1997.251">Menardi et al 1997</xref>, <xref ref-type="bibr" rid="aprt-def.REF.di_pietro.2007.73">Di Pietro et al 2007</xref>].</p>
          </list-item>
        </list>
        <table-wrap id="aprt-def.T.selected_aprt_allelic_variant" position="anchor" orientation="portrait">
          <label>Table 2. </label>
          <caption>
            <p>Selected <italic toggle="yes">APRT</italic> Allelic Variants</p>
          </caption>
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th id="hd_h_aprt-def.T.selected_aprt_allelic_variant_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Variant Classification</th>
                <th id="hd_h_aprt-def.T.selected_aprt_allelic_variant_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">DNA Nucleotide Change <break/>(Alias&#x000a0;<sup>1,&#x000a0;2</sup>)</th>
                <th id="hd_h_aprt-def.T.selected_aprt_allelic_variant_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Protein Amino Acid Change<break/>(Alias&#x000a0;<sup>1</sup>)</th>
                <th id="hd_h_aprt-def.T.selected_aprt_allelic_variant_1_1_1_4" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Reference Sequences</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td headers="hd_h_aprt-def.T.selected_aprt_allelic_variant_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                  <bold>Benign</bold>
                </td>
                <td headers="hd_h_aprt-def.T.selected_aprt_allelic_variant_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">c.297C&#x0003e;T</td>
                <td headers="hd_h_aprt-def.T.selected_aprt_allelic_variant_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Ala99=&#x000a0;<sup>3</sup><break/>(Ala99Ala)</td>
                <td headers="hd_h_aprt-def.T.selected_aprt_allelic_variant_1_1_1_4" rowspan="9" valign="middle" align="left" colspan="1">
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/NG_008013.1">NG_008013.1</ext-link>
                  <break/>
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/NM_000485.2">NM_000485.2</ext-link>
                  <break/>
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/protein/NP_000476.1">NP_000476.1</ext-link>
                </td>
              </tr>
              <tr>
                <td headers="hd_h_aprt-def.T.selected_aprt_allelic_variant_1_1_1_1" rowspan="8" valign="middle" align="left" scope="row" colspan="1">
                  <bold>Pathogenic</bold>
                </td>
                <td headers="hd_h_aprt-def.T.selected_aprt_allelic_variant_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">c.400+2dupT<break/>(400+2insT)<break/>(IVS4+2insT)</td>
                <td headers="hd_h_aprt-def.T.selected_aprt_allelic_variant_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td headers="hd_h_aprt-def.T.selected_aprt_allelic_variant_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.194A&#x0003e;T<break/>(1350A&#x0003e;T)</td>
                <td headers="hd_h_aprt-def.T.selected_aprt_allelic_variant_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Asp65Val</td>
              </tr>
              <tr>
                <td headers="hd_h_aprt-def.T.selected_aprt_allelic_variant_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.407T&#x0003e;C<break/>(2066T&#x0003e;C)</td>
                <td headers="hd_h_aprt-def.T.selected_aprt_allelic_variant_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Met136Thr</td>
              </tr>
              <tr>
                <td headers="hd_h_aprt-def.T.selected_aprt_allelic_variant_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.294G&#x0003e;A<break/>(1450G&#x0003e;A)</td>
                <td headers="hd_h_aprt-def.T.selected_aprt_allelic_variant_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Trp98Ter</td>
              </tr>
              <tr>
                <td headers="hd_h_aprt-def.T.selected_aprt_allelic_variant_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.258_261dupCCGA<break/>(1415_1418 insCCGA)&#x000a0;<sup>4</sup></td>
                <td headers="hd_h_aprt-def.T.selected_aprt_allelic_variant_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Lys88ProfsTer23<break/>(Arg87PfsTer23)</td>
              </tr>
              <tr>
                <td headers="hd_h_aprt-def.T.selected_aprt_allelic_variant_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.448G&#x0003e;T<break/>(2107G&#x0003e;T)</td>
                <td headers="hd_h_aprt-def.T.selected_aprt_allelic_variant_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Val150Phe</td>
              </tr>
              <tr>
                <td headers="hd_h_aprt-def.T.selected_aprt_allelic_variant_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.517_519delTTC<break/>(2179_2181 TTC deletion)</td>
                <td headers="hd_h_aprt-def.T.selected_aprt_allelic_variant_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Phe174del</td>
              </tr>
              <tr>
                <td headers="hd_h_aprt-def.T.selected_aprt_allelic_variant_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.542G&#x0003e;C<break/>(2201G&#x0003e;C)</td>
                <td headers="hd_h_aprt-def.T.selected_aprt_allelic_variant_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Ter181Ser</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn>
              <p>Note on variant classification: Variants listed in the table have been provided by the authors. <italic toggle="yes">GeneReviews</italic> staff have not independently verified the classification of variants.</p>
            </fn>
            <fn>
              <p>Note on nomenclature: <italic toggle="yes">GeneReviews</italic> follows the standard naming conventions of the Human Genome Variation Society (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://varnomen.hgvs.org/">varnomen.hgvs.org</ext-link>). See <related-object link-type="booklink" source-id="gene" document-id="app3" document-type="appendix">Quick Reference</related-object> for an explanation of nomenclature.</p>
            </fn>
            <fn id="aprt-def.TF.2.1">
              <label>1. </label>
              <p>Variant designation that does not conform to current naming conventions</p>
            </fn>
            <fn id="aprt-def.TF.2.2">
              <label>2. </label>
              <p>See <xref ref-type="bibr" rid="aprt-def.REF.boll_e.2010.679">Boll&#x000e9;e et al [2010]</xref>, <xref ref-type="bibr" rid="aprt-def.REF.harambat.2012.571">Harambat et al [2012]</xref>, <xref ref-type="bibr" rid="aprt-def.REF.ceballospicot.2014.241">Ceballos-Picot et al [2014]</xref> for a listing of the major variants.</p>
            </fn>
            <fn id="aprt-def.TF.2.3">
              <label>3. </label>
              <p>p.= designates that protein has not been analyzed, but no change is expected</p>
            </fn>
            <fn id="aprt-def.TF.2.4">
              <label>4. </label>
              <p>
                <xref ref-type="bibr" rid="aprt-def.REF.kamatani.1992.130">Kamatani et al [1992]</xref>
              </p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
        <p><bold>Normal gene product.</bold> APRT is a cytoplasmic enzyme that catalyzes the Mg<sup>++</sup>-dependent synthesis of 5&#x000b4;-adenosine monophosphate from adenine and 5-phosphoribosyl-1-pyrophosphate (PRPP) [<xref ref-type="bibr" rid="aprt-def.REF.sahota.2001">Sahota et al 2001</xref>]. The enzyme is a homodimer with each subunit consisting of 179 amino acid residues, yielding a molecular weight of 19,481 Daltons [<xref ref-type="bibr" rid="aprt-def.REF.sahota.2001">Sahota et al 2001</xref>].</p>
        <p>The crystal structure of recombinant human APRT in complex with adenosine monophsophate (AMP) has been determined [<xref ref-type="bibr" rid="aprt-def.REF.silva.2004.7663">Silva et al 2004</xref>]. The protein, which comprises nine &#x003b2;-strands and six &#x003b1;-helices, forms three domains:</p>
        <list list-type="bullet">
          <list-item>
            <p>A core that includes the PRPP-binding motif</p>
          </list-item>
          <list-item>
            <p>A flexible loop besides the core region which may be involved in the catalytic function</p>
          </list-item>
          <list-item>
            <p>A variable region primarily involved in base recognition</p>
          </list-item>
        </list>
        <p>From studies based on the crystallized enzyme in relation to clinically relevant pathogenic variants, the investigators predicted that water is an important element for PRPP binding [<xref ref-type="bibr" rid="aprt-def.REF.silva.2004.7663">Silva et al 2004</xref>].</p>
        <p><bold>Abnormal gene product.</bold> APRT activity in red cell lysates from individuals with APRT deficiency is typically less than 1% of control values [<xref ref-type="bibr" rid="aprt-def.REF.sahota.2001">Sahota et al 2001</xref>]. The two reported exceptions are:</p>
        <list list-type="bullet">
          <list-item>
            <p>The vast majority of affected individuals from Japan who are homozygotes or compound heterozygotes for the p.Met136Thr pathogenic variant, which decreases the affinity for the co-substrate PRPP compared with the wild-type enzyme, while the affinity for adenine is unchanged [<xref ref-type="bibr" rid="aprt-def.REF.sahota.2001">Sahota et al 2001</xref>]. The wild-type enzyme and the variant enzyme with the p.Met136Thr pathogenic variant have the same isoelectric point, but both forms can be detected by electrophoresis or by the increased Km for PRPP for the mutant enzyme.</p>
          </list-item>
          <list-item>
            <p>An individual of northern European heritage who had considerable residual enzyme activity in cell extracts but was a compound heterozygote for the c.400+2insT+2insT and p.Val150Phe pathogenic variants [<xref ref-type="bibr" rid="aprt-def.REF.deng.2001.260">Deng et al 2001</xref>]. Enzyme kinetic studies in this individual have not been reported.</p>
          </list-item>
        </list>
        <p><bold>APRT heterozygotes.</bold> Since APRT is a dimer of identical subunits, individuals who are heterozygous for a null mutation would be expected to have about 25% of normal enzyme activity in cell extracts. In the very few immunochemical studies that have been reported, immunoreactive protein in cell extracts from homozygous APRT-deficient individuals ranged from undetectable to normal, suggesting that, in the first instance, the protein was either not synthesized or was rapidly degraded, and in the second instance, the protein was synthesized but was non-functional.</p>
      </sec>
      <sec id="aprt-def.References">
        <title>References</title>
        <sec id="aprt-def.Literature_Cited">
          <title>Literature Cited</title>
          <ref-list id="aprt-def.Literature_Cited.reflist0">
            <ref id="aprt-def.REF.arnad_ttir.2014.316">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Arnad&#x000f3;ttir</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2014</year>
                <article-title>Febuxostat in adenosine phosphoribosyltransferase deficiency.</article-title>
                <source>Am J Kidney Dis.</source>
                <volume>64</volume>
                <fpage>316</fpage>
                <pub-id pub-id-type="pmid">24932691</pub-id>
              </element-citation>
            </ref>
            <ref id="aprt-def.REF.becker.2005.916">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Becker</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schumacher</surname>
                    <given-names>HR</given-names>
                    <suffix>Jr</suffix>
                  </name>
                  <name name-style="western">
                    <surname>Wortmann</surname>
                    <given-names>RL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>MacDonald</surname>
                    <given-names>PA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Palo</surname>
                    <given-names>WA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eustace</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vernillet</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Joseph-Ridge</surname>
                    <given-names>N</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout.</article-title>
                <source>Arthritis Rheum.</source>
                <volume>52</volume>
                <fpage>916</fpage>
                <lpage>23</lpage>
                <pub-id pub-id-type="pmid">15751090</pub-id>
              </element-citation>
            </ref>
            <ref id="aprt-def.REF.benedetto.2001.e37">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Benedetto</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Madden</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kurbanov</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Braden</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Freeman</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lipkowitz</surname>
                    <given-names>GS</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>Adenine phosphoribosyltransferase deficiency and renal allograft dysfunction.</article-title>
                <source>Am J Kidney Dis.</source>
                <volume>37</volume>
                <fpage>E37</fpage>
                <pub-id pub-id-type="pmid">11325702</pub-id>
              </element-citation>
            </ref>
            <ref id="aprt-def.REF.boll_e.2010.679">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Boll&#x000e9;e</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dollinger</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Boutaud</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Guillemot</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bensman</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Harambat</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Deteix</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Daudon</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Knebelmann</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ceballos-Picot</surname>
                    <given-names>I</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>Phenotype and genotype characterization of adenine phosphoribosyltransferase deficiency.</article-title>
                <source>J Am Soc Nephrol.</source>
                <volume>21</volume>
                <fpage>679</fpage>
                <lpage>88</lpage>
                <pub-id pub-id-type="pmid">20150536</pub-id>
              </element-citation>
            </ref>
            <ref id="aprt-def.REF.cassidy.2004.736">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Cassidy</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McCulloch</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fairbanks</surname>
                    <given-names>LD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Simmonds</surname>
                    <given-names>HA</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Diagnosis of adenine phosphoribosyltransferase deficiency as the underlying cause of renal failure in a renal transplant recipient.</article-title>
                <source>Nephrol Dial Transplant.</source>
                <volume>19</volume>
                <fpage>736</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">14767036</pub-id>
              </element-citation>
            </ref>
            <ref id="aprt-def.REF.ceballospicot.2014.241">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ceballos-Picot</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Daudon</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Harambat</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bensman</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Knebelmann</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Boll&#x000e9;e</surname>
                    <given-names>G</given-names>
                  </name>
                </person-group>
                <year>2014</year>
                <article-title>2,8-Dihydroxyadenine urolithiasis. A not so rare inborn error of purine metabolism.</article-title>
                <source>Nucleosides, nucleotides, and Nucleic Acids.</source>
                <volume>33</volume>
                <fpage>241</fpage>
                <lpage>52</lpage>
                <pub-id pub-id-type="pmid">24940675</pub-id>
              </element-citation>
            </ref>
            <ref id="aprt-def.REF.chiba.1988.141">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Chiba</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zwiauer</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>M&#x000fc;ller</surname>
                    <given-names>MM</given-names>
                  </name>
                </person-group>
                <year>1988</year>
                <article-title>Characterization of an adenine phosphoribosyltransferase deficiency.</article-title>
                <source>Clin Chim Acta.</source>
                <volume>172</volume>
                <fpage>141</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">3370830</pub-id>
              </element-citation>
            </ref>
            <ref id="aprt-def.REF.debray.1976.762">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Debray</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cartier</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Temstet</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cendron</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <year>1976</year>
                <article-title>Child's urinary lithiasis revealing a complete deficit in adenine phosphoribosyl transferase.</article-title>
                <source>Pediatr Res.</source>
                <volume>10</volume>
                <fpage>762</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">7766</pub-id>
              </element-citation>
            </ref>
            <ref id="aprt-def.REF.deng.2001.260">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Deng</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yang</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fr&#x000fc;nd</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wessel</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Abreu</surname>
                    <given-names>RA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tischfield</surname>
                    <given-names>JA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sahota</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>2,8-Dihydroxyadenine urolithiasis in a patient with considerable residual adenine phosphoribosyltransferase activity in cell extracts but with mutations in both copies of APRT.</article-title>
                <source>Mol Genet Metab.</source>
                <volume>72</volume>
                <fpage>260</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">11243733</pub-id>
              </element-citation>
            </ref>
            <ref id="aprt-def.REF.di_pietro.2007.73">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Di Pietro</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Perruzza</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Amorini</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Balducci</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ceccarelli</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lazzarino</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barsotti</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Giardina</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tavazzi</surname>
                    <given-names>B</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Clinical, biochemical and molecular diagnosis of a compound homozygote for the 254 bp deletion-8 bp insertion of the APRT gene suffering from severe renal failure.</article-title>
                <source>Clin Biochem.</source>
                <volume>40</volume>
                <fpage>73</fpage>
                <lpage>80</lpage>
                <pub-id pub-id-type="pmid">17126311</pub-id>
              </element-citation>
            </ref>
            <ref id="aprt-def.REF.edvardsson.2001.473">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Edvardsson</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Palsson</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Olafsson</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hjaltadottir</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Laxdal</surname>
                    <given-names>T</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>Clinical features and genotype of adenine phosphoribosyltransferase deficiency in iceland.</article-title>
                <source>Am J Kidney Dis.</source>
                <volume>38</volume>
                <fpage>473</fpage>
                <lpage>80</lpage>
                <pub-id pub-id-type="pmid">11532677</pub-id>
              </element-citation>
            </ref>
            <ref id="aprt-def.REF.edvardsson.2013.1923">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Edvardsson</surname>
                    <given-names>VO</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Goldfarb</surname>
                    <given-names>DS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lieske</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Beara-Lasic</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Anglani</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Milliner</surname>
                    <given-names>DS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Palsson</surname>
                    <given-names>R</given-names>
                  </name>
                </person-group>
                <year>2013</year>
                <article-title>Hereditary causes of kidney stones and chronic kidney disease.</article-title>
                <source>Pediatr Nephrol.</source>
                <volume>28</volume>
                <fpage>1923</fpage>
                <lpage>42</lpage>
                <pub-id pub-id-type="pmid">23334384</pub-id>
              </element-citation>
            </ref>
            <ref id="aprt-def.REF.fukuda.1996.123">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Fukuda</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tomatsu</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Masuno</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ogawa</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yamagishi</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rezvi</surname>
                    <given-names>GM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sukegawa</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shimozawa</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Suzuki</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kondo</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Imaizumi</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kuroki</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Okabe</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Orii</surname>
                    <given-names>T</given-names>
                  </name>
                </person-group>
                <year>1996</year>
                <article-title>Mucopolysaccharidosis IVA: submicroscopic deletion of 16q24.3 and a novel R386C mutation of N-acetylgalactosamine-6-sulfate sulfatase gene in a classical Morquio disease.</article-title>
                <source>Hum Mutat.</source>
                <volume>7</volume>
                <fpage>123</fpage>
                <lpage>34</lpage>
                <pub-id pub-id-type="pmid">8829629</pub-id>
              </element-citation>
            </ref>
            <ref id="aprt-def.REF.greenwood.1982.346">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Greenwood</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dillon</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Simmonds</surname>
                    <given-names>HA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barratt</surname>
                    <given-names>TM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pincott</surname>
                    <given-names>JR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Metreweli</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <year>1982</year>
                <article-title>Renal failure due to 2,8-dihydroxyadenine urolithiasis.</article-title>
                <source>Eur J Pediatr.</source>
                <volume>138</volume>
                <fpage>346</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">7128645</pub-id>
              </element-citation>
            </ref>
            <ref id="aprt-def.REF.harambat.2012.571">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Harambat</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Boll&#x000e9;e</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Daudon</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ceballos-Picot</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bensman</surname>
                    <given-names>A</given-names>
                  </name>
                  <collab>APRT Study Group</collab>
                </person-group>
                <year>2012</year>
                <article-title>Adenine phosphoribosyltransferase deficiency in children.</article-title>
                <source>Pediatr Nephrol.</source>
                <volume>27</volume>
                <fpage>571</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">22212387</pub-id>
              </element-citation>
            </ref>
            <ref id="aprt-def.REF.hidaka.1987.1409">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hidaka</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Palella</surname>
                    <given-names>TD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>O'Toole</surname>
                    <given-names>TE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tarle</surname>
                    <given-names>SA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kelley</surname>
                    <given-names>WN</given-names>
                  </name>
                </person-group>
                <year>1987</year>
                <article-title>Human adenine phosphoribosyltransferase. Identification of allelic mutations at the nucleotide level as a cause of complete deficiency of the enzyme.</article-title>
                <source>J Clin Invest.</source>
                <volume>80</volume>
                <fpage>1409</fpage>
                <lpage>15</lpage>
                <pub-id pub-id-type="pmid">3680503</pub-id>
              </element-citation>
            </ref>
            <ref id="aprt-def.REF.kamatani.1992.130">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kamatani</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hakoda</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Otsuka</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yoshikawa</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kashiwazaki</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <year>1992</year>
                <article-title>Only three mutations account for almost all defective alleles causing adenine phosphoribosyltransferase deficiency in Japanese patients.</article-title>
                <source>J Clin Invest.</source>
                <volume>90</volume>
                <fpage>130</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">1353080</pub-id>
              </element-citation>
            </ref>
            <ref id="aprt-def.REF.kamatani.1985.164">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kamatani</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Takeuchi</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nishida</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yamanaka</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nishioka</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tatara</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fujimori</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kaneko</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Akaoka</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tofuku</surname>
                    <given-names>Y</given-names>
                  </name>
                </person-group>
                <year>1985</year>
                <article-title>Severe impairment in adenine metabolism with a partial deficiency of adenine phosphoribosyltransferase.</article-title>
                <source>Metabolism.</source>
                <volume>34</volume>
                <fpage>164</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">3871499</pub-id>
              </element-citation>
            </ref>
            <ref id="aprt-def.REF.menardi.1997.251">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Menardi</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schneider</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Neuschmid-Kaspar</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Klocker</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hirsch-Kauffmann</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Auer</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schweiger</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>1997</year>
                <article-title>Human APRT deficiency: indication for multiple origins of the most common Caucasian mutation and detection of a novel type of mutation involving intrastrand-templated repair.</article-title>
                <source>Hum Mutat.</source>
                <volume>10</volume>
                <fpage>251</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">9298830</pub-id>
              </element-citation>
            </ref>
            <ref id="aprt-def.REF.nasr.2010.1909">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Nasr</surname>
                    <given-names>SH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sethi</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cornell</surname>
                    <given-names>LD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Milliner</surname>
                    <given-names>DS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Boelkins</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Broviac</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fidler</surname>
                    <given-names>ME</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>Crystalline nephropathy due to 2,8-dihydroxyadeninuria: an under-recognized cause of irreversible renal failure.</article-title>
                <source>Nephrol Dial Transplant.</source>
                <volume>25</volume>
                <fpage>1909</fpage>
                <lpage>15</lpage>
                <pub-id pub-id-type="pmid">20064951</pub-id>
              </element-citation>
            </ref>
            <ref id="aprt-def.REF.neetens.1986.93">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Neetens</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Van Acker</surname>
                    <given-names>KJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marien</surname>
                    <given-names>N</given-names>
                  </name>
                </person-group>
                <year>1986</year>
                <article-title>Corneal dystrophy and total adenine phosphoribosyltransferase (APRT) deficiency.</article-title>
                <source>Bull Soc Belge Ophtalmol.</source>
                <volume>213</volume>
                <fpage>93</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">3487363</pub-id>
              </element-citation>
            </ref>
            <ref id="aprt-def.REF.sahota.2001">
              <mixed-citation publication-type="book">Sahota AS, Tischfield JA, Kamatani N, Simmonds HA. Adenine phosphoribosyltransferase deficiency and 2,8-dihydroxyadenine lithiasis. In: Scriver CR, Sly WS, Valle D, Vogelstein B, Childs B, eds. <italic toggle="yes">The Metabolic and Molecular Bases of Inherited Disease</italic>. New York, NY: McGraw-Hill; 2001:2571-84.</mixed-citation>
            </ref>
            <ref id="aprt-def.REF.silva.2004.7663">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Silva</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Silva</surname>
                    <given-names>CH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Iulek</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thiemann</surname>
                    <given-names>OH</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Three-dimensional structure of human adenine phosphoribosyltransferase and its relation to DHA-urolithiasis.</article-title>
                <source>Biochemistry.</source>
                <volume>43</volume>
                <fpage>7663</fpage>
                <lpage>71</lpage>
                <pub-id pub-id-type="pmid">15196008</pub-id>
              </element-citation>
            </ref>
            <ref id="aprt-def.REF.wang.1999.78">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Wang</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ou</surname>
                    <given-names>X</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sebesta</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vondrak</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Krijt</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Elleder</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Poupetova</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ledvinova</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zeman</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Simmonds</surname>
                    <given-names>HA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tischfield</surname>
                    <given-names>JA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sahota</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>1999</year>
                <article-title>Combined adenine phosphoribosyltransferase and N-acetylgalactosamine-6-sulfate sulfatase deficiency.</article-title>
                <source>Mol Genet Metab.</source>
                <volume>68</volume>
                <fpage>78</fpage>
                <lpage>85</lpage>
                <pub-id pub-id-type="pmid">10479485</pub-id>
              </element-citation>
            </ref>
            <ref id="aprt-def.REF.zaidan.2014.2623">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Zaidan</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Palsson</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Merieau</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cornec-Le Gall</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Garstka</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Maggiore</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Deteix</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Battista</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gagn&#x000e9;</surname>
                    <given-names>ER</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ceballos-Picot</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Duong Van Huyen</surname>
                    <given-names>JP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Legendre</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Daudon</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Edvardsson</surname>
                    <given-names>VO</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Knebelmann</surname>
                    <given-names>B</given-names>
                  </name>
                </person-group>
                <year>2014</year>
                <article-title>Recurrent 2,8-dihydroxyadenine nephropathy: a rare but preventable cause of renal allograft failure.</article-title>
                <source>Am J Transplant.</source>
                <volume>14</volume>
                <fpage>2623</fpage>
                <lpage>32</lpage>
                <pub-id pub-id-type="pmid">25307253</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
      </sec>
      <sec id="aprt-def.Chapter_Notes">
        <title>Chapter Notes</title>
        <sec id="aprt-def.Author_Notes">
          <title>Author Notes</title>
          <p><bold>Vidar Orn Edvardsson, MD, Principal Investigator <break/>APRT Deficiency Research Program</bold>
Children&#x000b4;s Medical Center, Office 21-D Landspitali - The National University Hospital of Iceland Hringbraut, 101 Reykjavik, Iceland Tel: +354-543-1000; Fax: + 354-543-3021 E-mail: <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="vidare@landspitali.is">vidare@landspitali.is</email> and <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="rarekidneystones@landspitali.is">rarekidneystones@landspitali.is</email></p>
          <p><bold>Runolfur Palsson, MD, Co-Principal Investigator <break/>APRT Deficiency Research Program</bold>
Division of Nephrology, Office 14-F Landspitali - The National University Hospital of Iceland Hringbraut, 101 Reykjavik, Iceland Tel: +354-543-1000; Fax: + 354-543-6467 E-mail: <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="runolfur@landspitali.is">runolfur@landspitali.is</email> and <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="rarekidneystones@landspitali.is">rarekidneystones@landspitali.is</email></p>
          <p><bold>Amrik Sahota, PhD, Consultant<break/>APRT Deficiency Research Program</bold>Department of GeneticsLife Sciences BuildingRutgers University145 Bevier RoadPiscataway, NJ 08854, USATel: 732-445-7185; Fax: 732-445-1147E-mail: <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="sahota@biology.rutgers.edu">sahota@biology.rutgers.edu</email></p>
          <p>The official Web site of the Rare Kidney Stone Consortium: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://rarekidneystones.org">rarekidneystones.org</ext-link></p>
          <p>The APRT Deficiency Research Program at Landspitali &#x02013; The National University Hospital of Iceland, headed by Drs. Vidar Orn Edvardsson and Runolfur Palsson, is a part of the international Rare Kidney Stone Consortium (RKSC) (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://rarekidneystones.org">rarekidneystones.org</ext-link> and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://rarediseasesnetwork.epi.usf.edu/RKSC/index.htm">rarediseasesnetwork.epi.usf.edu/RKSC/index.htm</ext-link>) which was founded in 2009 with support from the National Institute of Diabetes and Digestive and Kidney Diseases and The Office of Rare Diseases Research at the US National Institutes of Health.</p>
          <p>
            <bold>Objectives of the APRT Deficiency Research Program</bold>
          </p>
          <list list-type="order">
            <list-item>
              <label>1</label>
              <p>Establish and expand an APRT Deficiency Registry.</p>
              <list list-type="alpha-lower">
                <list-item>
                  <label>a</label>
                  <p>Collection of longitudinal clinical data to study the epidemiology and natural history of the disorder.</p>
                </list-item>
                <list-item>
                  <label>b</label>
                  <p>Develop cohorts of well-characterized affected individuals for future clinical studies.</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <label>2</label>
              <p>Maintain and expand a biobank (DNA, urine, kidney tissue) at Landspitali &#x02013; The National University Hospital of Iceland.</p>
              <list list-type="alpha-lower">
                <list-item>
                  <label>a</label>
                  <p>All participating individuals will be offered genotyping.</p>
                </list-item>
                <list-item>
                  <label>b</label>
                  <p>Preparation for studies on the potential influence of modifying genes on the clinical expression of the disease.</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <label>3</label>
              <p>Increase awareness of APRT deficiency and facilitate timely diagnosis and treatment.</p>
              <list list-type="alpha-lower">
                <list-item>
                  <label>a</label>
                  <p>APRT Deficiency Support Network (APRTd.org) is an advocacy organization serving affected individuals and their families that was established early in 2011 with support from the APRT Deficiency Program.</p>
                </list-item>
                <list-item>
                  <label>b</label>
                  <p>Interaction with advocacy organizations, health care professionals and researchers facilitated through our website to further enhance the educational mission of this project and disseminate knowledge to the community.</p>
                </list-item>
                <list-item>
                  <label>c</label>
                  <p>Urinary DHA assay development</p>
                  <list list-type="roman-lower">
                    <list-item>
                      <label>i</label>
                      <p>Development of a UPLC-MS/MS method for diagnostic evaluation and monitoring of pharmacotherapy is in progress.</p>
                    </list-item>
                    <list-item>
                      <label>ii</label>
                      <p>Current work focuses also on the development of a urinary DHA screening assay for use in clinical laboratories.</p>
                    </list-item>
                  </list>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <label>4</label>
              <p>Identify APRT deficient patients at high risk of progressive loss of kidney function and stone formation.</p>
              <list list-type="alpha-lower">
                <list-item>
                  <label>a</label>
                  <p>Generate robust longitudinal outcome data through establishment of a prospective cohort of patients with APRT deficiency.</p>
                </list-item>
              </list>
            </list-item>
          </list>
          <p>The study is actively recruiting affected individuals from all around the world for the Registry and Biobank Protocols (RDCRN Protocols # 6401 and #6404).</p>
        </sec>
        <sec sec-type="ack" id="aprt-def.Acknowledgements">
          <title>Acknowledgements</title>
          <p>Authors V Edvardsson and R Palsson gratefully acknowledge the support of the Rare Kidney Stone Consortium (5U54DK083908-07), a part of the National Center for Advancing Translational Sciences (NCATS) Rare Diseases Clinical Research Network (RDCRN). RDCRN is an initiative of the Office of Rare Diseases Research (ORDR). The Rare Kidney Stone Consortium is funded through a collaboration between NCATS and National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). We thank Hrafnhildur Linnet Runolfsdottir, Medical Student, Faculty of Medicine, School of Health Sciences, University of Iceland, Reykjavik, Iceland, for generating the images of the urinary DHA crystals, and Sverrir Hardarson, MD, Department of Pathology, Landspitali &#x02013; The National University Hospital of Iceland, for providing the photomicrographs of the kidney biopsy specimens.</p>
        </sec>
        <sec id="aprt-def.Revision_History">
          <title>Revision History</title>
          <list list-type="bullet">
            <list-item>
              <p>18 June 2015 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>30 August 2012 (me) Review posted live</p>
            </list-item>
            <list-item>
              <p>2 May 2012 (ve) Original submission</p>
            </list-item>
          </list>
        </sec>
      </sec>
      <sec sec-type="figs-and-tables">
        <title/>
        <fig position="float" id="aprt-def.F1" orientation="portrait">
          <label>Figure 1. </label>
          <caption>
            <p>Urinary 2,8-dihydroxyadenine (DHA) crystals from an individual with adenine phosphoribosyltransferase deficiency. These crystals have a characteristic appearance and polarization pattern.A. Conventional light microscopy shows the typical brown DHA crystals. Note the dark outline and central spicules (original magnification x 400).B. The same field viewed with polarized light microscopy. The smaller crystals appear yellow and have a central Maltese cross pattern (original magnification x 400).</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="aprt-def-Image001" position="anchor" orientation="portrait"/>
        </fig>
        <fig position="float" id="aprt-def.F2" orientation="portrait">
          <label>Figure 2. </label>
          <caption>
            <p>Kidney biopsy findings from an individual with adenine phosphoribosyltransferase deficiency and kidney failure due to 2,8- dihydroxyadenine crystal nephropathyA. 2,8-dihydroxyadenine (DHA) crystals are seen within tubular lumens (arrows). Significant tubular atrophy, interstitial inflammation and fibrosis are present (hematoxylin and eosin stain; original magnification x 100).B. Higher magnification of the biopsy specimen shown in A. DHA crystals are seen within tubular lumens (long arrow), inside tubular epithelial cells (short arrow), and in the interstitium (arrowhead) (hematoxylin and eosin stain; original magnification x 400).C. The same microscopic field of the kidney biopsy specimen as shown in B viewed with polarized light microscopy. Crystals are seen within a tubular lumen (long arrow), inside tubular epithelial cells (short arrows) and in the interstitium (arrowheads) (hematoxylin and eosin stain; original magnification x 400).</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="aprt-def-Image002" position="anchor" orientation="portrait"/>
        </fig>
        <fig position="float" id="aprt-def.F3" orientation="portrait">
          <label>Figure 3. </label>
          <caption>
            <p>Algorithm for diagnostic evaluation of adenine phosphoribosyltransferase (APRT) deficiency and 2,8-dihydroxyadeninuriaFrom Edvardsson et al 2013. Used by permission.</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="aprt-def-Image003" position="anchor" orientation="portrait"/>
        </fig>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
